Trinity Biotech Plc Stock Performance
| TRIB Stock | USD 0.70 0.03 4.48% |
The entity has a beta of -0.13, which indicates not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Trinity Biotech are expected to decrease at a much lower rate. During the bear market, Trinity Biotech is likely to outperform the market. Trinity Biotech plc right now has a risk of 5.36%. Please validate Trinity Biotech sortino ratio, skewness, price action indicator, as well as the relationship between the potential upside and rate of daily change , to decide if Trinity Biotech will be following its existing price patterns.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Trinity Biotech plc has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong forward indicators, Trinity Biotech is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors. ...more
Last Split Factor 1:5 | Dividend Date 2015-07-01 | Ex Dividend Date 2015-06-05 | Last Split Date 2024-02-23 |
1 | Trinity Capital Inc. Provides 40 Million in Growth Capital to Paytient | 06/03/2025 |
2 | Dr. Phils TV network files for bankruptcy and sues distribution partner | 07/03/2025 |
3 | Trinity Industries Begins Dual Listing on NYSE Texas | 07/08/2025 |
4 | Listen Super League - Hull FC v Wakefield Trinity | 07/09/2025 |
5 | INSHUR receives 35m from Trinity Capital | 07/10/2025 |
6 | Three Days Left To Buy Trinity Industries, Inc. Before The Ex-Dividend Date | 07/11/2025 |
7 | Trinity Capital receives conditional approval to submit SBIC license application TRIN | 07/15/2025 |
8 | UBS Raises Price Target for Trinity Cap to 17.50 TRIN Stock News | 07/16/2025 |
9 | Trinity Capital Inc. Provides Alt Platform Inc. with up to 40 Million Asset Based Credit Facility | 07/18/2025 |
10 | Were still living an atomic nightmare | 07/22/2025 |
11 | Trinity Biotech Unveils CGM An AI-Native Platform Targeting the 260 Billion AI Wearable Market | 07/24/2025 |
| Begin Period Cash Flow | 3.7 M | |
| Total Cashflows From Investing Activities | -23 M |
Trinity Biotech Relative Risk vs. Return Landscape
If you would invest 76.00 in Trinity Biotech plc on April 28, 2025 and sell it today you would lose (6.00) from holding Trinity Biotech plc or give up 7.89% of portfolio value over 90 days. Trinity Biotech plc is currently generating 0.0022% in daily expected returns and assumes 5.3649% risk (volatility on return distribution) over the 90 days horizon. In different words, 48% of stocks are less volatile than Trinity, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Trinity Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Trinity Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Trinity Biotech plc, and traders can use it to determine the average amount a Trinity Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 4.0E-4
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | TRIB |
Estimated Market Risk
| 5.36 actual daily | 48 52% of assets are more volatile |
Expected Return
| 0.0 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Trinity Biotech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Trinity Biotech by adding Trinity Biotech to a well-diversified portfolio.
Trinity Biotech Fundamentals Growth
Trinity Stock prices reflect investors' perceptions of the future prospects and financial health of Trinity Biotech, and Trinity Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Trinity Stock performance.
| Return On Equity | -19.13 | ||||
| Return On Asset | -0.11 | ||||
| Profit Margin | (0.52) % | ||||
| Operating Margin | (0.43) % | ||||
| Current Valuation | 108.09 M | ||||
| Shares Outstanding | 18.63 M | ||||
| Price To Earning | 31.00 X | ||||
| Price To Book | 5.11 X | ||||
| Price To Sales | 0.20 X | ||||
| Revenue | 61.55 M | ||||
| Gross Profit | 21.44 M | ||||
| EBITDA | (16.91 M) | ||||
| Net Income | (31.79 M) | ||||
| Cash And Equivalents | 10.01 M | ||||
| Cash Per Share | 0.41 X | ||||
| Total Debt | 100.76 M | ||||
| Current Ratio | 3.66 X | ||||
| Book Value Per Share | (1.96) X | ||||
| Cash Flow From Operations | (4.19 M) | ||||
| Earnings Per Share | (1.80) X | ||||
| Market Capitalization | 12.49 M | ||||
| Total Asset | 103.29 M | ||||
| Retained Earnings | (79.12 M) | ||||
| Working Capital | 9.03 M | ||||
| Current Asset | 151 M | ||||
| Current Liabilities | 21 M | ||||
About Trinity Biotech Performance
By analyzing Trinity Biotech's fundamental ratios, stakeholders can gain valuable insights into Trinity Biotech's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Trinity Biotech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Trinity Biotech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 176.29 | 163.83 | |
| Return On Tangible Assets | (0.61) | (0.58) | |
| Return On Capital Employed | (0.30) | (0.28) | |
| Return On Assets | (0.31) | (0.29) | |
| Return On Equity | 0.90 | 0.95 |
Things to note about Trinity Biotech plc performance evaluation
Checking the ongoing alerts about Trinity Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Trinity Biotech plc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Trinity Biotech plc had very high historical volatility over the last 90 days | |
| Trinity Biotech plc has some characteristics of a very speculative penny stock | |
| Trinity Biotech plc has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 61.55 M. Net Loss for the year was (31.79 M) with profit before overhead, payroll, taxes, and interest of 21.44 M. | |
| Trinity Biotech plc currently holds about 10.01 M in cash with (4.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.41. | |
| Trinity Biotech plc has a poor financial position based on the latest SEC disclosures | |
| Roughly 12.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from gurufocus.com: Trinity Biotech Unveils CGM An AI-Native Platform Targeting the 260 Billion AI Wearable Market |
- Analyzing Trinity Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Trinity Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Trinity Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Trinity Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Trinity Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Trinity Biotech's stock. These opinions can provide insight into Trinity Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Trinity Stock analysis
When running Trinity Biotech's price analysis, check to measure Trinity Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Trinity Biotech is operating at the current time. Most of Trinity Biotech's value examination focuses on studying past and present price action to predict the probability of Trinity Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Trinity Biotech's price. Additionally, you may evaluate how the addition of Trinity Biotech to your portfolios can decrease your overall portfolio volatility.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |